Results 11 to 20 of about 1,482 (173)

Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study

Vaccines, 2022
Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 ...
Francesco Tassone, Simone Cappilli, Flaminia Antonelli, Ruggiero Zingarelli, Andrea Chiricozzi, Ketty Peris   +5 more
doaj   +1 more source

Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment

Przegląd Dermatologiczny, 2023
The existence of two types of alopecia areata is suggested (probably genetically different): early-onset, with more severe symptoms, longer disease duration, higher tendency to relapse, often with a positive family history, and late-onset, in which the ...
Adriana Rakowska, Lidia Rudnicka, Małgorzata Olszewska, Beata Bergler-Czop, Joanna Czuwara, Ligia Brzezińska-Wcisło, Joanna Narbutt, Waldemar Placek, Barbara Zegarska   +8 more
doaj   +1 more source

Real-World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi-Center Cohort Study. [PDF]

Clin Transl Sci
ABSTRACT The approval of baricitinib and ritlecitinib for alopecia areata (AA) marks the beginning of the Janus kinase (JAK) inhibitor era in AA treatment. Tofacitinib, a first‐generation JAK1/3 inhibitor, has theoretical potential to treat AA; however, real‐world evidence, particularly on comparative outcomes across patient subgroups and patient ...
Jin Y, Cao J, Yang S, Liu Y, Tang R, Zeng Y, Huang C, Luo Y.   +7 more
europepmc   +2 more sources

Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report

SAGE Open Medical Case Reports, 2023
Alopecia areata is a non-scarring, autoimmune hair loss disorder that is associated with inflammatory bowel disease. Alopecia areata and inflammatory bowel disease may have a common pathogenic mechanism that involves the Janus kinase/STAT pathway.
Leah A Johnston, Cathy Lu, Susan M Poelman   +2 more
doaj   +1 more source

¿Qué esconde la alopecia? Alopecia universalis como síntoma de inicio de un paciente seropositivo al VIH

Galicia Clínica, 2022
Highly active antiretroviral therapy has contributed to an increase of Human Immunodeficiency Virus (HIV) seropositive patients life expectancy. Because of that, comorbidities spectrum associated to this disease has been changing.
Marta Nobre Pereira, Ana Pimenta de Castro   +1 more
doaj   +1 more source

Microneedling with Triamcinolone acetonide versus Intralesional Triamcinolone acetonide in treatment of Alopecia Areata [PDF]

Al-Azhar International Medical Journal, 2023
Background: Alopecia areata (AA) is a widespread, non-scarring skin illness, triggered by T-cell-mediated autoimmune responses targeting hair follicles at anagen-stage. AA is a relatively frequent disease with a worldwide incidence of 1%-2%.
Bothina Ageeba, Amr Zaki, Emad Elrewiny
doaj   +1 more source

Bimatoprost in the treatment of eyelash universalis alopecia areata

International Journal of Trichology, 2010
To evaluate topical bimatoprost for eyelash growth in patients with alopecia areata (AA).A 1-year retrospective study, bilateral eyelash alopecia.Forty-one subjects with AA universalis without ocular disease applied 0.03% bimatoprost to the eyelid margin once a day over the course of 1 year.Thirty-seven subjects completed the study, one patient was ...
Vila, Teresa Ojeda, Camacho Martinez, Francisco M   +1 more
openaire   +3 more sources

Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecial Totalis and Alopecia Universalis: A Randomized, Double-Blind, Placebo-Controlled Trial

Siriraj Medical Journal, 2017
Background: Alopecia totalis (AT) and alopecia universalis (AU) have a high rate of recurrence and are very difficult to treat. To date, no consensus has been reach among clinicians regarding the best way to treat these conditions.
Rattapon Thuangtong, Supenya Varothai, Charussri Leeyaphan, Daranporn Triwongwaranat, Rasthawathana Deesomchoke, Sunatra Nitayavardhana   +5 more
doaj   +3 more sources

Adiponectin as a novel biomarker of disease severity in alopecia areata

Scientific Reports, 2021
The frequent coexistence of obesity and metabolic syndrome in patients with alopecia areata may indicate the common pathogenetic pathway in these conditions with an important role of adipokines.
Anna Stochmal, Anna Waśkiel-Burnat, Sylwia Chrostowska, Michał Zaremba, Adriana Rakowska, Joanna Czuwara, Lidia Rudnicka   +6 more
doaj   +1 more source

Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) [PDF]

J Cosmet Dermatol
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1‐RAs), a class of drugs indicated for diabetes mellitus and weight control, have been implicated in alopecia. We mined data from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to better understand the relationship between alopecia and GLP‐1‐RAs.
Gupta A, Teasell E, Bamimore M, Mirmirani P, Talukder M.   +4 more
europepmc   +2 more sources